AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Chargeurs

CR
Bloomberg   CRI FP
Support Services  /  France  Web Site   |   Investors Relation
Strong 2025 ambitions, luxury flavour
Pros
  • Chargeurs is focusing on no-nonsense profitable growth, with a keen eye for developing businesses in niche markets with a low capital intensity
  • The creation of Healthcare Solutions is proof of astute and effective management, becoming a fantastic asset that has helped the group leapfrog its diversification ambitions
  • The main business, Protective Films, has a remarkable FCF potential as the need for quality in industrial processes is so ubiquitous
Cons
  • The firm is small in absolute terms and may fall below most investors' radars
  • Challenging market conditions in the fashion industry will continue weighing on the activities of CFT-PCC in FY21, with a material recovery expected not until FY22
  • While Chargeurs' CEO has gained a large majority control of Columbus (30% controlling shareholder) in early 2019, which is good news for minorities, the detailed ownership of Columbus remains unknown
Updates
22/09/22 EPSFollowing the publication of the H1 22 res...
22/09/22 DCFOur DCF-based valuation sees a margina...
15/09/22 Other newsThe up-and-coming luxury player
12/09/22 EarningsH1 22: an encouraging start to FY 2022 d...
13/05/22 EarningsUpbeat start to 2022 propelled by strong ...
24/03/22 EPSWe have incorporated the FY21 figures, ...
24/03/22 NAVWe have adjusted the value of the differe...
24/03/22 DCFOur DCF-based valuation sees a margina...
18/02/22 EarningsFY21: CPF achieves record year, group’s...
11/11/21 EarningsQ3 performance confirms our FY view
23/09/21 LatestChange of valuation profile
13/09/21 EarningsH1 21: strong execution and record order...
05/05/21 TargetThe adjustments made to our FY21-22 E...
05/05/21 EPSFollowing the publication of the record Q...
05/05/21 EarningsProtective Films and Healthcare Solution...
29/04/21 TargetThe valuation increases across the differ...
29/04/21 EPSThe significant upgrade in our FY21-22 E...
29/04/21 NAVWe have updated our estimated NAV by i...
29/04/21 DCFThe rise in our DCF-based valuation is dri...
20/04/21 EPSWe have revised our earnings expectatio...
20/04/21 NAVThe valuation of Chargeurs' business line...
24/02/21 EarningsCHS leads FY20 record result as Charge...
28/01/21 EPSWe have raised our EPS estimates for F...
28/01/21 EarningsFY20 ends on a high note as Protective F...
11/11/20 EarningsHealthcare-led Q3 lifts full-year outlook
11/11/20 EPSOur FY20 EPS estimate increases on the...
14/09/20 TargetOur target price is virtually unchanged foll...
14/09/20 EPSOur FY20 EPS estimate sees a major up...
14/09/20 NAVOur NAV/SOTP valuation is mainly impac...
14/09/20 EarningsH1: an absolute home run
29/04/20 EarningsNew healthcare products activity unlocks ...
17/04/20 TargetThe cut to our target price reflects the mo...
17/04/20 EPSThe lower FY19 EPS reflect the costs rel...
17/04/20 NAVOur estimated NAV remains quite conser...
17/04/20 DCFWe maintain our base assumption which ...
14/04/20 LatestNew protective equipment activity to help ...
09/03/20 EarningsStaying on course with strategic roadmap...
03/02/20 EarningsFY19 sets a sound foundation for growth ...
28/01/20 M&A /Corp.Strategic move towards museum servicin...
28/01/20 TargetOur increased TP sees its biggest impact...
28/01/20 NAVWe have included the acquisition of D&P ...
18/11/19 EarningsQ3: another robust quarterly showing
18/11/19 EPSWe have slightly trimmed our 2019 EPS ...
23/09/19 EPSOur EPS estimates decreased on the bac...
23/09/19 DCFOur DCF valuation is impacted by our low...
18/09/19 EarningsH1: organic growth recovery and a bright...
05/07/19 M&A /Corp.Technical Substrates sprouting through a...
22/05/19 DCFMinor adjustments to reflect more modest...
07/05/19 EarningsSuccessful acquired growth offsets organ...
Target
Upside 157%
Price (€) 11.49
Market Cap (€M) 284
Perf. 1W: -7.34%
Perf. 1M: -25.2%
Perf. 3M: -27.8%
Perf Ytd: -53.3%
10 day relative perf. to stoxx600: -9.36%
20 day relative perf. to stoxx600: -15.8%